[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100144795":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":39,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":11,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Laboratoires Thea","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"T1225","EXPERIMENTAL",null,[13],"Drug: T1225",{"label":15,"type":16,"description":11,"interventionNames":17},"Tobramycin","ACTIVE_COMPARATOR",[18],"Drug: Tobramycin",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","one drop twice daily (morning and evening) in each eye from Day 0 to Day 2",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"1 to 2 drops every two hours while awake on Days 0-1, up to 8×\u002Fday, then 1 to 2 drops 4 times daily on Days 2-6",[15],[28],{"facility":11,"status":11,"city":29,"state":11,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":11},"Clermont-Ferrand","63000","France","FR",{"type":34,"coordinates":35},"Point",[36,37],3.08682,45.77969,{"lat":37,"lon":36},{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100144795","phase-3-clinical-efficacy-and-safety-of-t1225-versus-tobramycin-03--eye-drops-in-the-treatment-of-purulent-bacterial-conjunctivitis-of-children-100144795",true,"NCT01155999","Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.","Inclusion Criteria:\n\n* Age ≥ one day of life and ≤ 18 years\n* Purulent bacterial conjunctivitis",false,"ALL","1 Day","18 Years",{"count":52,"type":53},286,"ACTUAL","INTERVENTIONAL",[56],"PHASE3","Efficacy\u002FSafety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.",[59],"Purulent Bacterial Conjunctivitis","COMPLETED","2014-10-24",{"date":63,"type":64},"2014-10-29","ESTIMATED",{"date":66,"type":11},"2008-12",{"date":68,"type":53},"2011-02",{"name":5,"class":6},1]